GlassScriptPhysician profile
Patricia Hall
NPI 1932404662
$9,431.58
in general payments reported to CMS, 2019-2025
49 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,395 · 2020: $1,010 · 2021: $1,186 · 2022: $1,106 · 2023: $1,432 · 2024: $1,786 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,734.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,984.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,008.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $884.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $842.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $465.96 | 2020-2025 | |
| Amgen INC. | $421.25 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $413.52 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.89 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $302.10 | 2019-2021 | |
| Zealand Pharma US, INC. | $253.60 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $216.02 | 2022-2025 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $202.64 | 2019-2024 | |
| Valeritas, INC. | $200.17 | 2019 | |
| Mylan Specialty L.P. | $188.87 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $188.53 | 2019-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.